TB challenge over ‘missing’ millions


About three million people who developed tuberculosis in 2012 have been “missed” by health systems, the World Health Organization has said.

Finding these missed cases is one of the biggest challenges in TB care and control, the WHO’s report says.

Twelve countries including India, South Africa and Bangladesh account for the majority of undiagnosed individuals.

But the WHO says the target to halve the number of TB deaths by 2015 is still within reach.

Global TB programme director Dr Mario Raviglione said 56 million people had been cured and 22 million lives had been saved in the past 15 years and half of the highest-burden countries were on track to achieve the Millennium Development Goals targets, but there remained a number of major challenges.

“The two major challenges we identified are that of detecting in the system what we call the missed cases,” he told the BBC.

” There are about three million people that we estimate had TB and that are not officially in the system, that are not reported.

“Some of them may actually be never detected, some of them are in fact hidden in the private sector, in the non-state sector, that does not notify the cases.

“So that is I think one of the biggest challenges we have to face and there are opportunities there because we know where these cases may be.”

Drug-resistant TB challenge

The WHO says TB testing services need to be urgently improved in many countries, with help from non-governmental organisations NGOs and volunteers.

And in others, particularly Asian countries, more needs to be done to ensure figures on TB are compiled and reported centrally.

“Start Quote

Unless we take urgent action, we will continue to see an increase in harder-to-treat drug resistant strains of TB”

Dr Philipp du Cros Medecins Sans Frontieres

The other major challenge highlighted is drug-resistant TB.

The WHO estimates that 450,000 people became ill with multidrug-resistant TB (MDR-TB) in 2012. China, India and Russia have the highest rates.

But the report adds that by 2012, deaths from TB had been reduced by 45% since 1990, meaning the target of a 50% reduction by 2015 is within reach.

Bacteria

Charity Medecins Sans Frontieres’ (MSF) infectious disease specialist Dr Philipp du Cros said: “Three in four people with multidrug-resistant tuberculosis are still not diagnosed, and 17,000 of those diagnosed in 2012 did not even start treatment.”

He said: “These shocking figures are an indictment of the global failure to tackle drug-resistant tuberculosis head on. People are paying for this failure with their lives.”

Dr Du Cros added: “Unless we take urgent action, we will continue to see an increase in harder-to-treat drug resistant strains of TB.”

He said more research was needed to make treatments for TB shorter, more effective and less damaging for patients.

“An extra $2bn was needed to plug a funding gap in the treatment of TB, he added.

‘Dramatic’ drop in global HIV infections


The number of HIV infections and Aids-related deaths has fallen dramatically, according to a UN report.

Death rates fell from 2.3 million during its peak in 2005 to 1.6 million last year, says UNAIDS.

_70076607_viral_blood_cell_culture_in_tube-spl-1

The number of new HIV infections fell by a third since 2001 to 2.3 million.

Among children, the drop was even steeper. In 2001 there were more than half a million new infections. By 2012 the figure had halved to just over a quarter of a million.

The authors put the fall in deaths and infection rates in children down to better access to antiretroviral drugs which help suppress the virus.

Without treatment, people with HIV can go on to develop Aids which makes simple infections deadly.

By the end of 2012 almost 10m people in low and middle income countries, including South Africa, Uganda and India, were accessing antiretroviral therapy, according to the report.

The improved access is being attributed to drugs being more affordable and available in communities, as well as more people coming forward for help.

Way to go

According to UNAIDS, the world is “closing in” on its Millennium Development Goals to stop and reverse the Aids epidemic by 2015.

But it says the world can go beyond its target of getting 15m people on HIV treatment by 2015. The World Health Organization has now revised its guidelines making even more people eligible for treatment.

The report also found that progress has been slow in providing HIV services to people who are most at risk of infection, like those who inject drugs.

And it highlights the need to do more to deal with sexual violence against women and girls. They make up a key group of people vulnerable to infection.

Bev Collins, Health Policy Advisor at Doctors without Borders said: “Huge leaps forward have been made to make sure that millions of people – especially in the developing world – can access lifesaving HIV treatment at an affordable price.

“But this is no time for complacency. We need to keep on rolling out access to better treatment strategies, expanding access to accurate, cost-effective testing, and to care”

Noma: a neglected enigma.


Noma is a disease surrounded by riddles. It manifests itself only in the poorest populations in developing countries, enclosed by ignorance and extreme poverty. The worldwide prevalence of noma is unknown—estimates range from 30 000 to 140 000 cases.1 Most cases of noma worldwide occur in the so-called noma belt, which is situated directly south of the Sahara and runs across Africa from Senegal to Ethiopia. Another puzzle is that child mortality and malnutrition are prevalent on the Indian subcontinent, but noma is not reported there.23 The prevention and treatment of noma is not a priority in the countries where the disease is prevalent. Moreover, deaths from noma are not included in the mortality statistics of these countries. The cause of noma—the biological mechanism that ignites the gangrene—remains a mystery. Although the disease is clearly an opportunistic infection, we still do not know whether some of the commensal microorganisms in the oral microbiota play a particular part in the expanding gangrene. Also puzzling is how an unknown percentage (a common estimate suggests 10%) of noma patients survive the often extensive gangrene without any medical treatment. Antibiotic treatment of noma has not been subject to medical research, except for in some old observational studies.4 Furthermore, after one and a half centuries of surgical experiments, a good surgical treatment for a frequent sequela of noma, complete trismus of the mouth, has still not been found.5

The study by Baratti-Mayer and colleagues, undertaken in Niger, focuses on risk factors for noma. It is admirable that this large group of Swiss scientists, almost all members of the only scientific group on noma in the world, GESNOMA, has embarked on such a large and well-organised prospective, matched, case-control study to assess the risk factors for noma, and even more admirable that they have collected their data successfully under very difficult circumstances.

Their results confirm that malnutrition has a paramount role in the development of noma, and that poverty is associated with the disease. They also confirm a link between noma and recent illnesses of respiratory and intestinal origin. A new aspect to their study is the inventory of the oral microbiota in patients with noma and in controls. Their results do not confirm the role of Fusobacterium necrophorum (present in herbivores) as a trigger organism for noma, as suggested by Enwonwu and colleagues6 who hypothesised that the presence of herbivore livestock was a potential risk factor for noma. Baratti-Mayer and colleagues also describe differences in the intraoral microbiota of noma patients and controls, with a lower amount of Fusobacterium genus and spirochetes in patients with noma than in healthy controls. This result is intriguing because previous findings by Stewart,7 Eckstein,8 and Emslie9 showed the presence of spirilliform and fusiform microorganisms (called Borrelia vincenti and Fusiformis fusiformis at that time), often in large numbers, in biopsy samples taken from the transitional zone between the gangrene and healthy tissue, which suggested an important infiltrating role for these two microorganisms. In this context, the results of this study do not solve the puzzle of the trigger of this devastating gangrene but rather magnify it. Invasive diagnostics with, for example, needle biopsies from this transitional zone could help to elucidate the nature of this gangrene.

An interesting finding, which is not commented on in the Discussion section, is that all 82 patients with noma received amoxicillin and metronidazole, resulting in a mortality rate of 8·5%. This article is, as far as I know, the first publication reporting treatment results of a series of noma patients since 1966, when Michael Tempest reported a similar mortality rate of 8% in 250 patients treated with penicillin.4 This finding implies that a combination of amoxicillin and metronidazole is a good treatment to give to patients with noma, and perhaps also a penicillin, in view of the results of half a century ago.

However, a major problem is that most patients with noma worldwide do not have access to medical facilities because they are not available or are too expensive. Patients might consult a traditional healer, whose treatment (often a branding iron or caustic herbs) will lead to a deterioration in the patient’s condition. Western non-governmental organisations have also provided treatment in the past. Unfortunately, such programmes are now in jeopardy because of political instability and concomitant insecurity for aid workers from developed countries.

Noma is a disease that can be prevented completely by a particular level of economic welfare for the poorest people in society. This degree of welfare has been reached by most of the world’s population, which has expanded across the planet for thousands of years. An old companion on this journey of expansion, which is found on the edges of human being’s habitat (and is the case for every animal), is hunger and death. Death by starvation is expressed in many ways, of which noma is iconic as the “face of poverty”.10 We want to eradicate phenomena such as extreme poverty, famine, and starvation, as seen in the definition of the Millennium Development Goals and the recent G8 focus on nutrition. The future will show us whether or not these goals are the starting points of a feasible global health target.

References

1 Fieger A, Marck KW, Busch R, Schmidt A. An estimation of the incidence of noma in north-west Nigeria. Trop Med Int Health 2003; 8: 402-407. CrossRef | PubMed

2 Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 1969-1987. Summary | Full Text | PDF(1713KB) | CrossRef | PubMed

3 Gragnolati M, Shekar M, Das Gupta M, Bredenkamp C, Lee Y. India’s undernourished children: a call for reform and action.World Bank, 2005. http://siteresources.worldbank.org/SOUTHASIAEXT/Resources/223546-1147272668285/IndiaUndernourishedChildrenFinal.pdf. (accessed June 2, 2013).

4 Tempest MN. Cancrum oris. Br J Surg 1966; 53: 949-969. CrossRef | PubMed

5 Montandon D. Surgery of noma: a 20-year experience. Stomatologie 2007; 104: 1-9. PubMed

6 Falkler WA, Enwonwu CO, Idigbe EO. Isolation of Fusobacterium necrophorum from cancrum oris (noma). Am J Trop Med Hyg 1999; 60: 150-156. PubMed

7 Stewart MJ. Observations on the histopathology of cancrum oris. J Pathol 1912; 16: 221-225. PubMed

8 Eckstein A. Noma. Am J Dis Children 1940; 59: 219-237. PubMed

9 Emslie RD. Cancrum oris. Dent Pract Dent Rec 1963; 13: 481-495. PubMed

10 Marck KW. Noma, the face of poverty. Hannover: MIT-Verlag GmbH, 2003.

Source: Lancet

Sickle Cell Anaemia in a Changing World.


Populations and their health are dynamic. Societal, environmental, and economic changes lead to changes in rates of birth, death, and disease, often described as transitions in mortality, demography, and epidemiology. The notion of epidemiologic transition provides an insight into the relationship between levels of overall mortality and the distribution of its causes [1][3], in which the greatest changes arise from the survival of children and young women. Recent falls in global child mortality are good news [4], but will lead to increases in the relative burdens of morbidity and disability in children who would previously have died, and of congenital malformations and inherited disorders. The work of Frédéric Piel and colleagues on sickle cell anaemia (SCA), published in this week’s PLOS Medicine [5], speaks strongly to this point: SCA is an inherited disease whose global importance will increase in terms of absolute numbers and relative population burden. SCA occurs when individuals are homozygous for sickle haemoglobin (HbS) in place of normal adult haemoglobin, and is the most common form of sickle cell disorder (SCD) [6]. Piel and colleagues have collated HbS allele frequency surveys and used them in models to generate a global distribution map and estimate the numbers of infants born heterozygotic and homozygotic for HbS. Using population and mortality projections, they predict an increase in the numbers of newborns with SCA to over 400,000 in 2050. They also estimate the potential mortality effects of four care-provision scenarios, with a best-case scenario that between 7.5 and 15.5 million newborn lives could be saved, most of them in Africa.

Modelled estimates are a growth area in global health. Whilst useful at supra-national and national levels, their emergence highlights the lack of reliable data on populations, disease, and mortality across most of the world: precisely the sort of information that policy makers and health planners need. The utility of estimates for planning screening programmes, infrastructural and human resource requirements, and clinical care protocols at sub-national levels is likely to be limited where the generalisability of assumptions is challenged by diversity at the local level. Even at a global level, estimates can cause confusion. Research teams using different models may, for example, come to different conclusions [7]. Piel et al. have combined available data, statistical methods, and assumptions to predict current burdens and future trends. Their uncertainties are described clearly, and a preoccupation with methodological critiques can easily distract us from the public health concerns that estimates raise.

The epidemiologic transition has been reframed as a health transition that involves sociocultural, behavioural, and health service factors [8], and policy and health services must respond to changing disease burdens. Unfortunately, the notion of transitions is general. Parallel transitions are happening in different groups within one nation, the best example being differences between socioeconomic groups. Rates of transition vary with local environment, and counter-transition is even possible [9]. Policy makers must set priorities in an environment of multiple burdens, unfinished agendas, competing discourses, and the voices of interest groups[10], a process that has been described as a chaos of purposes and accidents [11]. In an environment of Realpolitik, the generation of estimates of burden is important for advocacy. Characteristically, investigators working in an important public health field that has not received global attention lay down the strategic epidemiology [7],[12], as Piel and colleagues are doing, demonstrating that lack of progress will hinder efforts to attain targets such as those of the Millennium Development Goals.

Quantifying the problem is important, but not sufficient. In a consideration of issue attention for newborn health, Jeremy Shiffman considered four elements: the power of the actors involved, new ideas that can be brought to the table, the characteristics of the issue in terms of attractiveness and tractability, and political context [13]. The kind of strategic epidemiology that the SCA figures exemplify needs to be linked with granular understanding of local epidemiology and service provision [7]. SCA poses a particular challenge in terms of tractability. Haematopoietic stem cell transplantation, an emerging cure, is currently too costly a technology for the countries on which the burden predominantly falls, as is hydroxyurea therapy for children at high risk of illness. Survival, health, and well-being can all be improved substantially, but rely on health care systems with a certain level of functionality. Piel and colleagues suggest that the priority is to identify births of infants with SCA, but that such births could be avoided through genetic counselling and prenatal diagnosis. Termination of pregnancy is one of several options, which include preconception genetic screening and strategic reproductive choices, education for carrier parents, and holistic management from infancy. Quite apart from the logistic and financial challenges, these approaches raise substantial ethical questions summarised in recent work from Ghana [14].

Several interventions would be enormously helpful. Routine newborn screening remains costly—but is likely to become less so—and may miss infants born at home. Penicillin prophylaxis and pneumococcal immunisation are possible in most health care systems. The most beneficial approach involves comprehensive care [15]: family education, routine immunisation, malaria prevention, nutrition and hydration, prophylactic antibiotics, folic acid supplements, transfusion when required, support groups for children and their families, protocols for the management of acute events by health workers and—most importantly—regular follow-up. Human resources for health need to be well trained, and the medicines required need to be affordable and available, including the pain relief required by many people with SCD [16].

Steps towards a systematic approach are being taken [17]. A 2006 World Health Assembly resolution on SCA recommends increased awareness in the international community and emphasises collaboration between countries, including technical support, development of practice models, and coordination [18]. The World Health Organization has published a strategy for the African Region, with targets that include development and implementation of national control programmes in member states with high SCD prevalence, adoption of comprehensive health care management, and establishment of surveillance systems [19]. The estimates from Piel and colleagues underscore the need for both collaborative responses and better data for planning and monitoring.

Source: PLOS

 

Time for the Big Push to Defeat Malaria.


Moments of historic greatness are rarely realized by a single actor. Instead, they require the work of partners, with a sense of shared responsibility and coordinated action. The Big Push to defeat malaria is no different. In the past 10 years, partners working together have reversed malaria’s spread and prevented millions of deaths, mostly of children under the age of five. Yet even with all that progress, malaria still claims a child’s life every minute. So we have more work to do. Science has given us the tools to defeat this disease. We will achieve greatness by getting it done.

Today we have insecticide-treated nets rather than just regular nets that last longer, significantly reducing costs. There are new drugs to tackle resistant strands and rapid diagnostic tests that allow us to identify kids that do and don’t have malaria. We are moving in the right direction. Global malaria mortality rates have dropped by 26 percent and half of the malaria endemic countries are on track to meeting the global target of reducing malaria case incidence by 75 percent by 2015.

As a global community, our fates are often more intertwined than we like to imagine. Controlling malaria isn’t only a prospect of preventing needless deaths, it is an economic imperative. Entrepreneurs, farmers and traders who are at home sick themselves or with their kids cost Africa an estimated $12 billion a year in productivity. Defeating malaria is one of the first steps we can take to speed up Africa-driven economic growth.

Later this year, the international community will gather to pledge money to the Global Fund for the next three years. In April, the Global Fund requested $15 billion from donors as an investment towards the historical opportunity of defeating these diseases. It’s the kind of investment where the return will be measured in lives saved, and the increased productivity of developing countries no longer burdened by deaths from mosquito bites.

Essential to maximizing these investments, African leaders will continue to demonstrate their own commitment to national health programs both financially and with human resources. The African Leaders Malaria Alliance, a consortium of 49 leaders from the continent, tracks country progress in preventing and treating the disease, with government leaders holding one another accountable to keep malaria a priority, while working towards the goal of near zero deaths by the end of 2015.

With less than 1,000 days until the clock runs out on the 2015 Millennium Development Goals, our resolve will be tested both before and after the zero hour. Meeting the health related MDGs would no doubt be a great accomplishment for our global brothers and sisters, but history will judge us by whether or not we fill our war chest and use our proven strategies and tools to defeat these diseases. As partners in this fight, this is our shared opportunity and responsibility.

Source: huffingtonpost.com